Entrada Therapeutics (TRDA) Preferred Stock Liabilities (2020 - 2021)
Entrada Therapeutics (TRDA) recorded quarterly Preferred Stock Liabilities of $197.5 million in Q3 2021, little changed quarter-over-quarter from $197.5 million in Q2 2021, and up 141.85% on a YoY basis from $81.7 million in Q3 2020.
Entrada Therapeutics (TRDA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $197.5 million for Q3 2021.
- In Q3 2021, Preferred Stock Liabilities rose 141.85% year-over-year to $197.5 million; the TTM figure through Sep 2021 stood at $197.5 million (up 141.85% YoY), while the FY2020 annual figure was $81.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $197.5 million for Q3 2021 at Entrada Therapeutics, roughly flat from $197.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $197.5 million in Q1 2021 to a low of $81.7 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 197.49 Mn |
| Jun 30, 2021 | 197.49 Mn |
| Mar 31, 2021 | 197.49 Mn |
| Dec 31, 2020 | 81.66 Mn |
| Sep 30, 2020 | 81.66 Mn |